Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × OTHER_GOV × Paclitaxel × Clear all

Phase

Phase 2 18 Phase 3 4 Phase EARLY_PHASE1 1 Phase 4 1 Phase 2/3 1 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

INDUSTRY 172 OTHER 154 NIH 44 NETWORK 15 OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 1

Interventions

fludarabine 5 Nivolumab 5 Cyclophosphamide 5 Radiotherapy 3 Metformin 3 Melphalan 3 Interleukin-2 3 pembrolizumab 2 fludarabine phosphate 2 S 1 (combination) 2 Irinotecan 2 Ipilimumab 2 tremelimumab 1 selinexor 1 olaparib 1 nabiximols 1 ivarmacitinib 1 durvalumab 1 defactinib 1 decitabine and cedazuridine drug combination 1 cedazuridine 1 carfilzomib 1 apatorsen 1 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 1 Topotecan 1 Rituximab 1 Radiosurgery 1 Radiation 1 Pemetrexed 1 Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01133912 2012-01-04

PGT

National Cancer Center, Korea

Phase 1 Completed

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡